Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore. Founded in , genOway is a global biotechnology company offering preclinical models and solutions to leading bio-pharmaceutical companies and academic institutions for ultimate predictability. Based on its core business and leading expertise in custom-designed preclinical models of high predictability, the company has developed its own catalog of translational models with a primary focus on immuno-oncology and immunotherapy.
The company aims at providing unmatched preclinical solutions that predict the success of a molecule in order to accelerate next-generation drugs to patients.
Our vision is to provide Ultimate Predictability in preclinical research thanks to both an unrivaled intimate collaboration with our clients and strong scientific expertise in designing genetically modified models and understanding biological physiology. Our broad technologic and scientific platform enables the design and creation of models for research, target validation, drug screening, efficacy, and non-regulatory safety testing. The value of the scientific data obtained from these models is proportional to the quality of the model design.
Thus, the generation of the right research or preclinical model requires a thorough analysis of the target gene biology paired with a clear assessment of the specificities of each customer project. We invest heavily in our consulting activity, especially to create new models, but also to contribute to the experimental design and analyze the data with the ultimate objective to maximize the predictability of the data produced.
When creating a new model for a client, genOway provides an integrated service consisting of performing the first phenotyping studies, evaluating the model's main physiological characteristics once the first animals are available, and handling line amplification. This provides clients with cohorts ready for experimentation and enables them to focus on their specific in vivo or in vitro studies. We have built a unique license portfolio for all technologies used, including exclusive licenses, which we are allowed to sublicense.
